235 related articles for article (PubMed ID: 29768414)
1. Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.
Fernández O; Izquierdo G; Fernández V; Leyva L; Reyes V; Guerrero M; León A; Arnaiz C; Navarro G; Páramo MD; Cuesta A; Soria B; Hmadcha A; Pozo D; Fernandez-Montesinos R; Leal M; Ochotorena I; Gálvez P; Geniz MA; Barón FJ; Mata R; Medina C; Caparrós-Escudero C; Cardesa A; Cuende N;
PLoS One; 2018; 13(5):e0195891. PubMed ID: 29768414
[TBL] [Abstract][Full Text] [Related]
2. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA
Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548
[TBL] [Abstract][Full Text] [Related]
3. Adipose Mesenchymal Stromal Cell-Based Therapy for Severe Osteoarthritis of the Knee: A Phase I Dose-Escalation Trial.
Pers YM; Rackwitz L; Ferreira R; Pullig O; Delfour C; Barry F; Sensebe L; Casteilla L; Fleury S; Bourin P; Noël D; Canovas F; Cyteval C; Lisignoli G; Schrauth J; Haddad D; Domergue S; Noeth U; Jorgensen C;
Stem Cells Transl Med; 2016 Jul; 5(7):847-56. PubMed ID: 27217345
[TBL] [Abstract][Full Text] [Related]
4. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.
Llufriu S; Sepúlveda M; Blanco Y; Marín P; Moreno B; Berenguer J; Gabilondo I; Martínez-Heras E; Sola-Valls N; Arnaiz JA; Andreu EJ; Fernández B; Bullich S; Sánchez-Dalmau B; Graus F; Villoslada P; Saiz A
PLoS One; 2014; 9(12):e113936. PubMed ID: 25436769
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study.
Kumar H; Ha DH; Lee EJ; Park JH; Shim JH; Ahn TK; Kim KT; Ropper AE; Sohn S; Kim CH; Thakor DK; Lee SH; Han IB
Stem Cell Res Ther; 2017 Nov; 8(1):262. PubMed ID: 29141662
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial.
Harris VK; Stark J; Williams A; Roche M; Malin M; Kumar A; Carlson AL; Kizilbash C; Wollowitz J; Andy C; Gerber LM; Sadiq SA
Stem Cell Res Ther; 2024 May; 15(1):151. PubMed ID: 38783390
[TBL] [Abstract][Full Text] [Related]
7. The role of nonautologous and autologous adipose-derived mesenchymal stem cell in acute pyelonephritis.
Sabetkish S; Sabetkish N; Talebi MA; Halimi S; Kajbafzadeh AM
Cell Tissue Bank; 2018 Sep; 19(3):301-309. PubMed ID: 29218427
[TBL] [Abstract][Full Text] [Related]
8. Intrathecal transplantation of autologous adipose-derived mesenchymal stem cells for treating spinal cord injury: A human trial.
Hur JW; Cho TH; Park DH; Lee JB; Park JY; Chung YG
J Spinal Cord Med; 2016 Nov; 39(6):655-664. PubMed ID: 26208177
[TBL] [Abstract][Full Text] [Related]
9. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.
Connick P; Kolappan M; Crawley C; Webber DJ; Patani R; Michell AW; Du MQ; Luan SL; Altmann DR; Thompson AJ; Compston A; Scott MA; Miller DH; Chandran S
Lancet Neurol; 2012 Feb; 11(2):150-6. PubMed ID: 22236384
[TBL] [Abstract][Full Text] [Related]
10. Intra-discal injection of autologous, hypoxic cultured bone marrow-derived mesenchymal stem cells in five patients with chronic lower back pain: a long-term safety and feasibility study.
Elabd C; Centeno CJ; Schultz JR; Lutz G; Ichim T; Silva FJ
J Transl Med; 2016 Sep; 14(1):253. PubMed ID: 27585696
[TBL] [Abstract][Full Text] [Related]
11. Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study.
Bonab MM; Sahraian MA; Aghsaie A; Karvigh SA; Hosseinian SM; Nikbin B; Lotfi J; Khorramnia S; Motamed MR; Togha M; Harirchian MH; Moghadam NB; Alikhani K; Yadegari S; Jafarian S; Gheini MR
Curr Stem Cell Res Ther; 2012 Nov; 7(6):407-14. PubMed ID: 23061813
[TBL] [Abstract][Full Text] [Related]
12. Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial.
Freitag J; Bates D; Wickham J; Shah K; Huguenin L; Tenen A; Paterson K; Boyd R
Regen Med; 2019 Mar; 14(3):213-230. PubMed ID: 30762487
[No Abstract] [Full Text] [Related]
13. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
[TBL] [Abstract][Full Text] [Related]
14. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
15. Additional benefit of combined therapy with melatonin and apoptotic adipose-derived mesenchymal stem cell against sepsis-induced kidney injury.
Chen HH; Lin KC; Wallace CG; Chen YT; Yang CC; Leu S; Chen YC; Sun CK; Tsai TH; Chen YL; Chung SY; Chang CL; Yip HK
J Pineal Res; 2014 Aug; 57(1):16-32. PubMed ID: 24761983
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal properties of SJL mice-stem cells and their efficacy as autologous therapy in a relapsing-remitting multiple sclerosis model.
Marin-Bañasco C; Suardíaz García M; Hurtado Guerrero I; Maldonado Sánchez R; Estivill-Torrús G; Leyva Fernández L; Fernández Fernández O
Stem Cell Res Ther; 2014 Dec; 5(6):134. PubMed ID: 25498031
[TBL] [Abstract][Full Text] [Related]
17. Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells.
Ra JC; Kang SK; Shin IS; Park HG; Joo SA; Kim JG; Kang BC; Lee YS; Nakama K; Piao M; Sohl B; Kurtz A
J Transl Med; 2011 Oct; 9():181. PubMed ID: 22017805
[TBL] [Abstract][Full Text] [Related]
18. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
19. Intravenous administration of xenogenic adipose-derived mesenchymal stem cells (ADMSC) and ADMSC-derived exosomes markedly reduced brain infarct volume and preserved neurological function in rat after acute ischemic stroke.
Chen KH; Chen CH; Wallace CG; Yuen CM; Kao GS; Chen YL; Shao PL; Chen YL; Chai HT; Lin KC; Liu CF; Chang HW; Lee MS; Yip HK
Oncotarget; 2016 Nov; 7(46):74537-74556. PubMed ID: 27793019
[TBL] [Abstract][Full Text] [Related]
20. Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis.
Harris VK; Stark J; Vyshkina T; Blackshear L; Joo G; Stefanova V; Sara G; Sadiq SA
EBioMedicine; 2018 Mar; 29():23-30. PubMed ID: 29449193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
